IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Systemic Reactions to Allergen Immunotherapy Amd Skin Testing (chackos)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Allergy skin tests and allergen immunotherapy are common procedures for both the diagnosis and treatment of atopic diseases. Allergen immunotherapy has proved to be effective in reducing the symptoms of allergic rhinitis and asthma1-2. Despite its clinical benefit, there is risk of systemic reactions associated with these procedures.
The systemic reaction rate to skin testing for aeroallergens is significant lower than the rate of reactions to immunotherapy, but it is not negligible. Lin et al reported only 2 patients who had systemic allergic reactions to skin testing for respiratory allergies in 10,400 patients tested.3 They determined the overall risk of inducing anaphylactic reactions by skin testing to be less than 0.02% and other studies have produced similar results.4-5 The rate of systemic reactions to skin testing is likely underscored. Thompson et. al reported a systemic reaction rate of 6% of patients receiving skin testing.6 It is important to recognize the risk of systemic reactions seeing skin testing is commonly done. It is also imperative to recognize the treatments for these reactions to prevent progression.
Hypothesis The systemic reaction rate to allergen immunotherapy and skin testing to aeroallergens is higher than previously reported. Biphasic anaphylactic reactions rarely occur with allergen immunotherapy and skin testing.
| Condition |
|---|
| SYSTEMIC REACTION |
| Study Type: | Observational |
| Study Design: | Time Perspective: Retrospective |
| Official Title: | Systemic Reactions to Allergen Immunotherapy Amd Skin Testing |
- This is a prospective observational study of patients who are having either skin testing or allergen immunotherapy for the diagnosis or treatment of allergic rhinitis, conjunctivitis, and/or asthma.
| Estimated Enrollment: | 100 |
| Study Start Date: | August 2006 |
| Study Completion Date: | June 2007 |
| Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
CHART REVIEW ONLY
CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
|
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Male and female subjects who are receiving skin testing or allergen immunotherapy from one allergy practice.
Exclusion Criteria:
- NON Male and female subjects who are receiving skin testing or allergen immunotherapy from one allergy practice.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00594802
| United States, Florida | |
| USF | |
| Tampa, Florida, United States, 33613 | |
| Principal Investigator: | RICHARD F LOCKEY, MD | USF DIRECTOR OF ALLERGY AND IMMUNOLOGY |
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | DR. RICHARD F LOCKEY, UNIVERSITY OF SOUTH FLORIDA |
| ClinicalTrials.gov Identifier: | NCT00594802 History of Changes |
| Other Study ID Numbers: |
systemic reaction protocol |
| Study First Received: | January 4, 2008 |
| Last Updated: | August 5, 2010 |
Keywords provided by University of South Florida:
|
ALLERGIC REACTION |
ClinicalTrials.gov processed this record on July 21, 2017